Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 15;7(2):e656. doi: 10.1097/TXD.0000000000001113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 1. — Serum creatinine (blue line, left vertical axis) and plasma donor-derived cell-free DNA (dd-cfDNA) (orange line, right vertical axis) levels during and after pembrolizumab (anti-PD-1) therapy. The dd-cfDNA assay measures the amount of dd-cfDNA as a percentage of the total cell-free DNA circulating in plasma. The dashed horizontal line marks the lower limit of detection of the dd-cfDNA assay (0.19%); points along this line indicate undetectable levels of dd-cfDNA. Red arrowhead indicates the patient’s final dose of pembrolizumab. anti-PD-1, anti-programmed cell death protein 1.